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The 1997 UK government white paper “The New NHS: Modern, Dependable”1, introduced a legal requirement for the NHS to provide 
accountable and quality assured services. 
Clinical governance was described by Scally and 
Donaldson (1998) as the “… system through 
which NHS organisations are accountable for 
continuously improving the quality of their 
services and safeguarding high standards of care 
by creating an environment in which excellence 
in clinical care will flourish.” An organisational 
culture that “…creates a working environment 
which is open and participative, where ideas and 
good practice are shared, where education and 
research are valued…. is likely to be one where 
clinical governance thrives.” 
Importantly, the latter part of this quote 
implies that research will underpin clinical 
governance (CG) activities. To a lesser degree, 
other CG targets including the development 
and impact of Continuing Personal and 
Professional Development (CPPD), service 
redesign and even the implementation of 
CG activities will themselves need to be 
monitored and reviewed. Clearly, the research 
methodologies appropriate to these different 
areas will need to be wide-ranging. 
Research Governance (RG) has also rapidly 
developed over the last few years, especially 
post the publication of the 2001 Department of 
Health (DoH) Research Governance Framework 
for Health and Social Care2 and subsequent 
changes to the way research ethics committees 
work. As Kerrison et al3 explain:
“The research governance framework sets in 
place mechanisms for ensuring that research 
complies with all professional, ethical, legal, 
and scientific standards… From April 2004, 
all research conducted in care organisations 
must have a research sponsor… The primary 
role of NHS trusts in the framework is as care 
organisations. Care organisations must ensure 
that all research on NHS patients… NHS staff 
and research carried out in NHS premises, is 
conducted according to the framework.”
Directives from the European Union also bring 
in new guidance and rulings on best practice 
in research. An example of this is Directive 
2001/20/EC on Good Clinical Practice in Clinical 
Trials4, which will is due to come into legal force 
in all EU member states on May 1st 2004. 
NHS modernisation has given Primary Care 
Trusts (PCTs) unprecedented autonomy, but it 
also makes them accountable for any services 
they commission. Therefore, if Complementary 
and Alternative Medicine (CAM) services are to 
be integrated into the NHS, the development 
of CG (with its imperatives and processes 
for ensuring accountability and quality 
improvement) will be a crucial consideration 
for PCTs developing CAM services. Being able to 
demonstrate CAM’s benefits, cost-savings and 
effectiveness would validate those who proclaim 
the advantages of integrated healthcare in 
the NHS. Among these advantages is the 
potential to help PCTs meet key targets in the 
government’s modernisation agenda (i.e. a more 
primary care-led NHS, with fewer secondary 
care referrals and reduced prescribing rates). 
It will require a great deal of sound and highly 
efficient research to determine these outcomes.
As CAM integrates with the NHS, several 
factors relevant to the clinical governance of 
CAM are likely to influence policy formation 
in PCTs. Research conducted by the Medical 
Care Research Unit (MRCU) at the University of 
Sheffield5 identifies a number of key overlaps as 
being crucial to commissioning CAM services:
l   Equity of access
l   Cost effectiveness
l   Local priorities
l   Adequacy of the evidence base for CAM
l    Availability of appropriate quality assurance 
indicators
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The Government’s response to the House of 
Lords Select Committee scientific report on 
CAM6 reinforces this idea: “CAM can also play 
a part in treating NHS patients. But if it aspires 
to be an equal player with other forms of NHS 
treatment, it must meet the same standards 
required of them. And it must be clear and 
realistic about the contributions it can make.”7 
The headline NHS priorities (e.g. waiting lists, 
national priority conditions, and National Service 
Frameworks) will also influence, for better or 
worse, the development of CAM services. 
The Department of Health (DoH) and the King’s 
Fund have funded a three-year project, based 
at the School of Integrated Health, University 
of Westminster to address the issue of clinical 
governance for CAM NHS primary care services. 
Part of this work is to facilitate the process of 
developing consensus on best practice. Several 
important CG areas were prioritised at an 
initial stakeholder event and were subsequently 
addressed in a series of six seminars, hosted by 
the King’s Fund. The first seminars addressed 
key issues relating to evaluation and research, 
and this was followed later in the series with a 
seminar on economic evaluation. 
The seminars were attended by a broad range 
of stakeholders who heard presentations on 
current thinking by relevant experts followed by 
groupwork on specific topics, with the aim of 
drafting guidance on how to apply CG activities 
to CAM practice, as well as identifying the 
necessary steps and resources needed to help 
the process evolve.
Following the seminars, a modified Delphi 
technique8 was used to generate ‘expert’ 
feedback on the seminar outputs. The results 
of this process are being published in a 
consultation document9 this month. Over 1500 
individual stakeholders are being included in the 
consultation.
Evaluation & outcomes
One of the most interesting outputs from the 
series of seminars was the development of a 
pilot series of Broad Evidence Synthesis Topic on 
CAM (BESTCAM) reports, which was proposed 
by Kate Thomas, Deputy Director of the MCRU. 
Widely cited sources of evidence (such as 
Cochrane, York University, and Bandolier), which 
pull together the available evidence, focus 
exclusively on RCTs and frequently conclude 
that there is “no good evidence” relating to 
CAM. Kate Thomas and Dr Michael Dixon (Chair 
of the NHS Alliance) both made the case for 
returning to the original definition of evidence-
based medicine (EBM): “the integration of the 
best research evidence and evidence gleaned 
from clinical experience and influenced by 
patient values and preferences”. The true 
intention of EBM will be lost if decision-makers 
focus exclusively on randomised controlled trials 
as the only definitive source of evidence. 
“The true intention of 
EBM will be lost if 
decision-makers focus 
exclusively on randomised 
controlled trials as the 
only definitive source 
of evidence.”
Randomised controlled trials into the efficacy of 
CAM are rather sparse and the results of their 
systematic review inconclusive. Because this 
evidence is so under-developed and so much 
at variance with the impression of those who 
use CAM, there will be value in incorporating 
evidence on applying CAM in practice. 
Efficacy vs effectiveness
The efficacy versus effectiveness debate is 
concerned with the discrepancy between 
the results of controlled clinical trials and 
more pragmatic evaluation of practice as it 
happens in the clinical setting. Efficacy is 
high on internal validity at the expense of 
generalisability; effectiveness is high on external 
validity at the expense of careful controls. The 
research community favours efficacy while the 
practice community prefers effectiveness. The 
disparity has practical consequences in that 
healthcare delivery is influenced increasingly 
by the development of practice guidelines 
based on research data. It is entirely proper 
that evidence should be the foundation of 
effective healthcare delivery. The debate has to 
do with what constitutes the best evidence for 
clinical decisions. The BESTCAM reports aim to 
address this issue by incorporating a range of 
effectiveness studies of alongside the efficacy 
evidence.
The debate on EBM continues to be a hot 
topic for GPs11: “…the evidence-based 
medicine movement is evolving. It retains the 
fundamental premise that the efficacy and 
safety of interventions should be assessed in 
population-based research studies using the 
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tools of objective scientific measurement, 
with special status rightly accorded to the 
randomised controlled trial. But it increasingly 
recognises three additional areas of interest, 
which might be termed the ‘interface zones’ 
between evidence-based medicine and the 
real world, and which, I contend, require the 
research methods of the social sciences as 
well as (and sometimes instead of) those of 
biomedical science.
The three ‘interface zones’ are:
1.    The “… historical, political, economic and 
cultural” context within which “clinical 
research trials are planned, funded, 
undertaken (or abandoned), analysed, 
discussed, published (or withheld from 
publication) and disseminated.” These must 
be “defined and understood.”
2.    The “large gap between established 
evidence of efficacy research trials and 
delivering effective practice requires 
attention to both clinical outcomes and 
socio-cultural aspects of professional 
behaviour and organisational change.”
3.    “The clinical encounter…must be separately 
studied by appropriate techniques… [as it] 
is an interpretive and creative act that goes 
beyond objective scientific enquiry.”
Examining different types of 
evidence
Pooled RCT evidence on CAM is patchy, making 
it hard to draw definitive conclusions; yet 
decisions are usually made on this basis. 
A different approach is therefore required, 
as Kate Thomas pointed out in the first 
CG seminar12: “We cannot move forward 
if we require the highest level of proof of 
effectiveness [for every therapy in relation to 
every patient condition]. We will deny patients 
the benefit if we insist on that.” 
Discussion in the seminars focused on the value 
of non-RCT data in informing best practice, the 
development of new services, and the application 
of methodologies for assessing good quality 
research and reviewing non-RCT data in a robust 
and systematic way. Ways of supporting good 
practice in clinical governance for CAM services 
will need to be found, primarily in the generation 
of Performance Indicators (PIs).
Pilot BEST CAM Report
Participants at the DoH/King’s Fund seminar 
favoured broadening both the types of evidence 
and the methodologies employed, including:
l   Effectiveness of service delivery
l   Impact on prescribing rates
l   Secondary care referrals
l   Waiting times for orthodox treatments
l    GP and other primary care practitioners’ 
consultation rates
l   Workload 
l   Accessibility
Cost-effectiveness, benefits, and safety were 
also considered important. It was also generally 
acknowledged that a wide set of health 
outcomes should be included (quality of life, 
well-being, early return to work, etc.) Patient 
experience and satisfaction were high on 
agenda, as was acceptability to patients and 
referring GPs. Patient-led research was also 
identified as important.
The reports would cover either single treatment 
modalities or multiple treatment options for 
specific conditions. Priority conditions were 
those that are traditionally expensive to treat in 
terms of finance and resources, are related to 
National Service Frameworks (NSFs), or address 
other local and national priorities:
l   Patient choice, access, and safety
l   Demand management
l    Perceived effectiveness gaps within 
orthodox medicine
l   Unmet or poorly met needs
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Delegates were pragmatic about how BEST CAM 
reports should develop over time, the initial 
priority being those conditions and treatments 
where relevant evidence is available. As a result 
of this work, a pilot BEST CAM report is being 
developed by the CG team for the treatment 
of low back pain, in tandem with the pilot 
development of an integrated therapeutic 
pathway.
Performance indicators 
The generation of PIs is an example of applied 
research in CG, central to service evaluation and 
development. More crucially, services will not be 
funded without them. They need to be realistic 
and have a clear rationale, (e.g. evidence that a 
certain service delivered to x number of patients 
can reduce secondary referrals).
Delegates agreed that PIs should be generated 
in four key areas:
l   Safety
l   Effectiveness and efficacy
l   Delivery 
l   Value for money
Areas relating to safety included: adverse 
events, risk assessment, and health and safety 
procedures. Indicators were seen as essential 
for specific and non-specific conditions, and 
for a range of health outcomes including 
symptomatic relief, functional improvement, 
well-being, patient enablement and health 
promotion in chronic disease, lifestyle changes 
and the impact on patients’ ability to cope, their 
improved productivity, and impact on family life. 
Patient feedback, expectations and satisfaction 
were also considered highly relevant.
Economic evaluation
Valid economic evaluations of all health and 
social care interventions, including CAM, are 
absolutely essential. In many ways, economic 
evaluation of CAM is no different from that 
of conventional medicine, and the same could 
be argued for its clinical evaluation. Yet the 
challenges involved raise questions about how 
best to evaluate not only CAM but conventional 
care too!
The imperative of the ‘single metric’ in economic 
evaluation is at the heart of the problem: 
economists would like to produce generalisable 
outcomes, so they can assess whether CAM is 
doing something different when compared to 
other treatments - to see, for instance, whether 
treatments for back pain are better value for 
money than treatments for knee pain. Feedback 
is needed from economists on how separate 
empirical evidence from speculation. There is 
a great deal of intuitive understanding about 
‘expanded benefits’ from CAM, but how do 
we measure different kinds of benefit, and, 
more importantly, explore the relative value 
that patients attach and their preferences for 
different outcomes? 
Discussion, both in the seminars and through 
the ensuing Delphi process, revolved around the 
potential for evaluating the cost-effectiveness 
of CAM. Among the diverse strands of current 
economic thinking and research, there are 
examples of ways to take into account wider 
outcomes and associated costs. An example of 
this would be to track patients with low back 
pain with and without CAM interventions, and 
to compare this with orthodox treatment. The 
longer-term and wider implications would then 
be assessed (e.g. time off work, dependency 
on other family members, social benefits due 
to incapacity to work, the impact of early 
intervention on prevention of acute chronic 
recurrences, and so on). As Dr Mike Dixon, Chair 
of the NHS Alliance pointed out14:
“Integrating CAM is not just about introducing 
a new treatment, it is about changing the way 
we view ourselves and our capacity for self 
healing. That is the added benefit CAM could 
bring to the NHS, but it is one that is difficult 
for the health economists to quantify… Unless 
we look at the whole picture — the culture, 
population, community regeneration, the 
individual consultation — we will continue to 
view it solely in conventional terms. We need to 
get away from this reductionist approach, which 
characterises modern medicine today.”
The cost/benefit analysis of CAM will make no 
sense unless we bear in mind the wide range of 
perceived benefits, and the patient’s perspective 
on the benefits they would like to receive. This 
raises the issue of whether the NHS ought to be 
providing those kinds of benefits, and what an 
NHS-appropriate definition of health might be? 
This last question is perhaps the most central. 
Four domains of benefit call for immediate 
study:
l   Health status
l   Well-being
l   Process utilities
l    Health behaviours (which would include the 
dis-benefits of conventional treatment side 
effects)
Delegates proposed that the scope of evaluation 
should be widened, leading to the development 
and application of more appropriate and 
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relevant research methodologies.  Whilst 
recognising a need to incorporate current 
orthodox practice in the evaluation of CAM 
(in particular through the application of 
innovative models, such as Program Budgeting 
and Marginal Analysis - PBMA11), there was 
a consensus that any research should ask 
questions that are both relevant to CAM and 
appropriate to commonly associated outcomes. 
As well as more direct health gain, these 
might include longer-term evaluations of the 
impact on the individual and their immediate 
family, and wider costs to the social system 
as a whole. Examples include early return 
to work, maintaining family cohesiveness 
(especially where carers are concerned) as well 
as claims on the benefits system. This also 
relates to the prevention of clinical sequelae 
and the possibility that a CAM consultation 
can contribute to a person’s empowerment 
for health promotion and self-management. 
National and local priorities around patient-
choice and health promotion mean exploring 
methodologies that could measure outcomes 
related to these initiatives. 
Networks for CAM research
Networks for CAM researchers are already 
evolving across the UK, some with online 
facilities15. The Integrated Healthcare Network16 
is a site dedicated to professionals with an 
interest in developing CAM primary care 
services, including clinical governance and 
related research. It is jointly run as part of 
the Clinical Governance Project, University 
of Westminster and the Prince of Wales’s 
Foundation for Integrated Healthcare. 
In conclusion
There is a developing ethos of CG 
supporting research across conventional 
and complementary medicines. A three-year 
programme of DoH/King’s Fund seminars 
and other activities is working to develop 
an approach to research that teases out the 
complexities of efficacy versus effectiveness, and 
varied methodologies whilst accommodating the 
growing demands for economic justification of 
treatment funding. 
Jane Wilkinson (cgcam-net@wmin.ac.uk) is Senior 
Research Fellow and Manager of the Clinical Governance 
for CAM in Primary Care project at the School of Integrated 
Health. Professor David Peters is Clinical Director of the 
School, University of Westminster. 
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